Skip to main content

Table 3 RAASi discontinuation, down-titration and up-titration, by potassium category

From: A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure

 

Monthly probability of RAASi max discontinuation (%)

Monthly probability of RAASi max down-titration (%)

Monthly probability of RAASi sub-max discontinuation (%)

Source

SoC

Patiromer

SoC

Patiromer

SoC

Patiromer

Month 2–3

34.438% (6.589%)

3.336% (2.421%)

35.549% (6.589%)

0.000% (0.000%)

34.438% (6.589%)

3.336% (2.421%)

OPAL-HK [43]

Subsequent months

 K +  ≤ 5

2.600% (0.009%)

0.181%

1.800% (0.026%)

1.800%

2.600% (0.009%)

0.181%

Linde et al. (2019) [23]

 K +  > 5 to ≤ 5.5

3.029% (0.102%)

0.211%

2.617% (0.102%)

2.617%

3.029% (0.102%)

0.211%

 K +  > 5.5 to ≤ 6

4.547% (0.230%)

0.319%

5.306% (0.230%)

5.306%

4.547% (0.230%)

0.319%

 K +  > 6

10.000% (0.663%)

0.721%

8.900% (0.638%)

8.900%

10.000% (0.663%)

0.721%

  1. RAASi Renin–angiotensin–aldosterone system inhibitor, K + Potassium, SE Standard error, SoC Standard of care
  2. Note: Complete derivation described further in Supplemental Appendix A